Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to MTA3 (ENSG00000303185, LOC105374555), refers to a long non-coding RNA annotated in the human genome, transcribed from the strand opposite to the MTA3 gene. Its function is not experimentally characterized, but by analogy to other natural antisense transcripts, it could potentially regulate the expression or processing of the overlapping MTA3 gene[1][2][3]. Antisense RNAs can influence sense gene transcripts by mechanisms such as affecting transcript stability, processing, and chromatin environment, yet there is no evidence that this specific transcript is a receptor, enzyme, transporter, or therapeutic target, nor is it directly implicated in any disease process or drug pathway[1][2][3]. Novel transcript, antisense to MTA3" (ENSG00000303185, LOC105374555) is a bioinformatically-predicted or experimentally observed non-coding RNA antisense to the MTA3 gene. It is not a receptor, enzyme, transporter, or therapeutic target, and there is no evidence of drug interactions, biomarker utility, or disease linkage specific to this transcript[1][2][3].
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to MTA3 (LOC105374555).